Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Since data has long shown that rates of eczema -- clinically known as atopic dermatitis -- increase along with ...

Once thought to primarily affect children, data show it’s now ... “Although nutrition cannot treat eczema,” Morin said, “ensuring that we provide the body with nutrients to support skin health and ...

The malaria parasite may be gaining resistance against artemisinin, the drug most often used to try and save children with ...